12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lu AA21004: Phase III data

Top-line data from a double-blind, U.S. Phase III trial in 614 patients aged 18-75 with MDD showed that Lu AA21004 significantly improved MADRS scores from baseline vs. placebo. Lu AA21004 was generally well tolerated with nausea, headache, diarrhea and vomiting reported as the most common adverse events. Patients received once-daily 15 or 20 mg Lu AA21004,...

Read the full 260 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >